Clincosm LogoSign in Get a demo

Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in Fatty Liver

Sponsor
Cairo University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05623930
Collaborator
(none)
60
Enrollment
1
Location
2
Arms
5.6
Anticipated Duration (Months)
10.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)

Condition or Disease Intervention/Treatment Phase
  • Device: laser acupuncture
  • Other: wet cupping
 N/A

Detailed Description

In fatty liver patients,applied cupping (with scarification) will be compared, regarding its effect on antioxidant, lipid metabolism, cardioautonomic functions, and blood measures (glucose, inflammatory markers, liver enzymes), to application of laser on acupoints

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Hepatic Enzymes and Metabolic-Risk Factors Responses to Laser Acupuncture Versus Cupping Therapy in Fatty Liver
Actual Study Start Date :
Oct 12, 2022
Anticipated Primary Completion Date :
Apr 1, 2023
Anticipated Study Completion Date :
Apr 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: laser on acupuncture points

In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian

Device: laser acupuncture
In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
Active Comparator: cupping (with scarification)

in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.

Other: wet cupping
in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.

Outcome Measures

Primary Outcome Measures

  1. high density lipoprotein [12 weeks]

    it is a component of lipid profile

Secondary Outcome Measures

  1. cholesterol [12 weeks]

    it is a component of lipid profile

  2. low density lipoprotein [12 weeks]

    it is a component of lipid profile

  3. triglycerides [12 weeks]

    it is a component of lipid profile

  4. blood glucose [12 weeks]

    fasting level of blood glucose will be measured

  5. C reactive protein [12 weeks]

    high sensitivity levels C reactive protein will be measured

  6. Malondialdehyde [12 weeks]

    it ts oxidative stress marker

  7. aspartate transaminase [12 weeks]

    it is a hepatic enzyme that reports the functions of liver

  8. alanine transaminase [12 weeks]

    it is a hepatic enzyme that reports the functions of liver

  9. systolic blood pressure [12 weeks]

    it will be measured by sphygmomanometer

  10. diastolic blood pressure [12 weeks]

    it will be measured by sphygmomanometer

  11. pulse rate [12 weeks]

    it will be measured manually

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • fatty liver obese patients
Exclusion Criteria:

thoracic diseases heart diseases kidney diseases

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cairo Unoversity Giza Egypt

Sponsors and Collaborators

  • Cairo University

Investigators

  • Principal Investigator: Ali Ismail, lecturer, Cairo University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ali Mohamed Ali ismail, lecturer of Physical Therapy for Cardiovascular / Respiratory Disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Cairo University
ClinicalTrials.gov Identifier:
NCT05623930
Other Study ID Numbers:
  • P.T.REC/012/004116
First Posted:
Nov 21, 2022
Last Update Posted:
Nov 21, 2022
Last Verified:
Nov 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Fatty Liver

Study Results

No Results Posted as of Nov 21, 2022